Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PRIME Study: Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients

NCT05037461 is registered in ClinicalTrials.gov with J.M. de Laat as lead sponsor.

NCT NCT05037461
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05037461 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PRIME Study: Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 Patients
Lead sponsor
J.M. de Laat
Phase
Not applicable
Overall status
Active, not recruiting
Start date
June 27, 2022
Completion date
July 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple endocrine neoplasia type 1, neuroendocrine tumor of pancreas